Precision Biosciences Stock Performance
| DTIL Stock | USD 5.15 0.15 3.00% |
Precision BioSciences has a performance score of 1 on a scale of 0 to 100. The company holds a Beta of 2.02, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Precision BioSciences will likely underperform. Precision BioSciences right now holds a risk of 3.72%. Please check Precision BioSciences standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to decide if Precision BioSciences will be following its historical price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Precision BioSciences are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite quite persistent forward indicators, Precision BioSciences is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors. ...more
Actual Historical Performance (%)
One Day Return 3 | Five Day Return 11.96 | Year To Date Return 9.81 | Ten Year Return (99.02) | All Time Return (99.02) |
Last Split Factor 1:30 | Last Split Date 2024-02-14 |
1 | Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Societ... | 05/14/2025 |
2 | HC Wainwright Reaffirms Buy Rating for Precision BioSciences | 05/21/2025 |
3 | Disposition of 9826 shares by Brown Melinda of Precision BioSciences subject to Rule 16b-3 | 05/27/2025 |
4 | Acquisition by John Kelly of 82750 shares of Precision BioSciences subject to Rule 16b-3 | 06/02/2025 |
5 | Acquisition by Frankel Stanley of 21000 shares of Precision BioSciences subject to Rule 16b-3 | 06/06/2025 |
6 | Acquisition by Germano Geno J of 21000 shares of Precision BioSciences subject to Rule 16b-3 | 06/09/2025 |
7 | Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy | 06/25/2025 |
8 | Long Term Investment Analysis - news.stocktradersdaily.com | 07/01/2025 |
9 | Disposition of 14827 shares by John Kelly of Precision BioSciences at 4.26 subject to Rule 16b-3 | 07/03/2025 |
10 | Precision Biosciences CFO Sells Shares to Cover Tax Obligations - TradingView | 07/08/2025 |
11 | Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting ... | 07/16/2025 |
12 | What analysts say about Precision BioSciences Inc. stock - Unprecedented profit potential - Autocar Professional | 07/21/2025 |
13 | Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy | 07/23/2025 |
| Begin Period Cash Flow | 116.7 M | |
| Total Cashflows From Investing Activities | -215 K |
Precision | Build AI portfolio with Precision Stock |
Precision BioSciences Relative Risk vs. Return Landscape
If you would invest 511.00 in Precision BioSciences on April 28, 2025 and sell it today you would earn a total of 4.00 from holding Precision BioSciences or generate 0.78% return on investment over 90 days. Precision BioSciences is currently generating 0.081% in daily expected returns and assumes 3.7182% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Precision, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Precision BioSciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Precision BioSciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Precision BioSciences, and traders can use it to determine the average amount a Precision BioSciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0218
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | DTIL | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.72 actual daily | 33 67% of assets are more volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Precision BioSciences is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Precision BioSciences by adding it to a well-diversified portfolio.
Precision BioSciences Fundamentals Growth
Precision Stock prices reflect investors' perceptions of the future prospects and financial health of Precision BioSciences, and Precision BioSciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Precision Stock performance.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.43) % | ||||
| Operating Margin | (762.48) % | ||||
| Current Valuation | 9.63 M | ||||
| Shares Outstanding | 11.09 M | ||||
| Price To Earning | (6.10) X | ||||
| Price To Book | 1.16 X | ||||
| Price To Sales | 1.12 X | ||||
| Revenue | 68.7 M | ||||
| Gross Profit | 51.14 M | ||||
| EBITDA | 13.53 M | ||||
| Net Income | 7.17 M | ||||
| Cash And Equivalents | 184.14 M | ||||
| Cash Per Share | 1.66 X | ||||
| Total Debt | 30.05 M | ||||
| Debt To Equity | 0.27 % | ||||
| Current Ratio | 4.59 X | ||||
| Book Value Per Share | 4.68 X | ||||
| Cash Flow From Operations | (58.45 M) | ||||
| Earnings Per Share | (2.87) X | ||||
| Market Capitalization | 57.1 M | ||||
| Total Asset | 136.39 M | ||||
| Retained Earnings | (482.46 M) | ||||
| Working Capital | 80.01 M | ||||
| Current Asset | 174.05 M | ||||
| Current Liabilities | 23.86 M | ||||
About Precision BioSciences Performance
By examining Precision BioSciences' fundamental ratios, stakeholders can obtain critical insights into Precision BioSciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Precision BioSciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 275.53 | 244.91 | |
| Return On Tangible Assets | 0.05 | 0.06 | |
| Return On Capital Employed | (0.22) | (0.23) | |
| Return On Assets | 0.05 | 0.06 | |
| Return On Equity | 0.13 | 0.13 |
Things to note about Precision BioSciences performance evaluation
Checking the ongoing alerts about Precision BioSciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Precision BioSciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Precision BioSciences had very high historical volatility over the last 90 days | |
| Precision BioSciences has high likelihood to experience some financial distress in the next 2 years | |
| Precision BioSciences currently holds about 184.14 M in cash with (58.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66. | |
| Latest headline from finance.yahoo.com: Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy |
- Analyzing Precision BioSciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Precision BioSciences' stock is overvalued or undervalued compared to its peers.
- Examining Precision BioSciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Precision BioSciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Precision BioSciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Precision BioSciences' stock. These opinions can provide insight into Precision BioSciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.87) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.